Muhib Khan, MD
Vascular Neurology · Rochester, MNNPI 1043452337
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,000 of the $7,783 with a category attached, or 64.2%. Genentech USA, Inc. accounts for 66.1% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $5,308 and has fallen 99.5% since, to $29 in 2024.
Across 36 payments — averaging $216.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$5K
- Medtronic$2K
- Microtransponder, Inc.$486
- Novartis$194
- Genentech, Inc.$131
- Novo Nordisk$64
- plus $71 from 3 others
Across 1 payment — averaging $5569.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$6K
What the payments were for
- Consulting fees$5,00064%
- Travel & lodging$6258%
- Food & beverage$2,15728%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 3 | $5,143 |
| Medtronic(2 entities) | 16 | $1,695 |
| Microtransponder, Inc. | 3 | $486 |
| Novartis | 7 | $194 |
| Genentech, Inc. | 2 | $131 |
| Novo Nordisk | 2 | $64 |
| Portola Pharmaceuticals, LLC | 1 | $33 |
| UCB, Inc. | 1 | $20 |
| Neurelis, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Activase$5,103
- TNKase$5,103
- Cathflo Activase$5,000
- INTELLIS ADAPTIVESTIM$509
How this compares
Too few vascular neurology providers in Minnesotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atorvastatin Calcium | 18 | $179 |
| ClopidogrelClopidogrel Bisulfate | 12 | $37 |
Paid to pharmacies, not to this prescriber.
Other vascular neurology in Rochester
- Paul PetersonSaint Cloud$3K
- Benjamin MillerMinneapolis$743
- Smit ShahSaint Cloud$618
- Allison HoMinneapolis$595
- Sheetal PatelSaint Paul$343
- Farid KhasiyevMinneapolis$43
- Adel ElnasharMinneapolis$24
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.